Revolution Medicines (RVMDW) Stock Price, News & Analysis

Company Overview

Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.

Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants. These programs are being evaluated as both monotherapies and in combination with existing treatments to determine safety, tolerability and preliminary efficacy in patients with solid tumors.

Headquartered in Redwood City, California, the company was founded in 2015 and completed its initial public offering in August 2020. Its research and development operations leverage structure-based drug design and proprietary chemistry platforms to accelerate the discovery of next-generation RAS pathway inhibitors.

Under the leadership of President and Chief Executive Officer Roger DiPiazza, Revolution Medicines has established collaborations with leading biopharmaceutical partners to extend its global reach and advance its oncology pipeline. The company continues to explore novel therapeutic opportunities aimed at improving outcomes for patients with RAS-driven cancers worldwide.

Key Stats

• Today's Range: $11.03 to $11.67
• 50-Day Range: $5.04 to $11.62
• 52-Week Range: $0.16 to $11.67
• Volume: 7,888 shs
• Average Volume: 118,772 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RVMDW
• CIK: 1628171
• Web: www.revmed.com
• Phone: 650-481-6801
• Fax: N/A
• Employees: 378
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A